Phase 2 study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma
. J Clin Oncol 2009; 27:4068-75.
Renal cell carcinoma comprises more than 90% of all malignancies of the kidney.(2) For advanced or metastatic renal cell carcinoma
that is difficult to treat with surgery, the standard treatment method is molecular targeted drug therapy, however with low 5-year survival rates, this remains a disease with significant unmet medical needs.
CD10 expression in cutaneous adnexal neoplasms and a potential role for differentiating cutaneous metastatic renal cell carcinoma
. Arch Pathol Lab Med.
Trends over time in (A) the performance of lymphadenectomy (for definitions based on [greater than or equal to]3 and [greater than or equal to]8 lymph nodes removed); (B) median survival and Kaplan-Meier survival probabilities; and (C) adjusted cancer-specific survival for metastatic renal cell carcinoma
patients, Surveillance, Epidemiology, and End Results registry 1988-2011.
According to the results of this study, lenvatinib plus everolimus showed superior PFS over everolimus alone which is recommended by the National Comprehensive Cancer Network guidelines as a 2nd-line therapy for unresectable advanced or metastatic renal cell carcinoma
PAX-2 is a helpful marker for diagnosing metastatic renal cell carcinoma
: comparison with the renal cell carcinoma marker antigen and kidney-specific cadherin.
Disease-specific survival in de novo metastatic renal cell carcinoma
in the cytokine and targeted therapy era.
Under the Phase 2 clinical development, CRLX101 has been dosed in more than 250 patients and has Fast Track designation in combination with Avastin in metastatic renal cell carcinoma
(mRCC) following progression through two or three prior lines of therapy.
Expression of PAX-2, RCCM, and KSC in Metastatic Renal Cell Carcinomas
PAX-2, RCCM, KSC, No.
In a pre-specified exploratory sub-group analysis based on the International Metastatic Renal Cell Carcinoma
Database Consortium risk model, ORR was 42% in patients with intermediate/poor prognostic risk.
Following its approval in 2012, INLYTA has become a standard of care for second-line advanced RCC and has been used by an estimated 12,000 metastatic renal cell carcinoma
patients in the United States.
Hypo-fractionated Stereotactic Extra- Cranial Radiosurgery(HFSR) for Primary and Metastatic Renal Cell Carcinoma
. Int J Radiat Oncol Biol Phys 2006;66:S349.